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osteoclastogenesis than IL6, suggesting the role of different regulatory
mechanisms governing TNFa and IL6 action on bone metabolism.Bone Biology
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PROTEOMIC ANALYSIS OF OSTEOBLASTS SECRETOME PROVIDES
NEW INSIGHTS IN MECHANISMS UNDERLYING OSTEOARTHRITIS
SUBCHONDRAL BONE SCLEROSIS
C. Sanchez, G. Mazzucchelli, C. Lambert, F. Comblain, E. DePauw,
Y. Henrotin. Univ. of Liege, Liege, Belgium
Purpose: Osteoarthritis (OA) is characterized by cartilage degradation
but also by other joint tissues modiﬁcations like subchondral bone
sclerosis. In this study, we used a proteomic approach to compare
secretome of osteoblast isolated from sclerotic (SC) or non sclerotic
(NSC) area of OA subchondral bone.
Methods: Secretome was analyzed using differential quantitative and
relative label free analysis on nanoUPLC G2 HDMS system. mRNA of the
more differentially secreted proteins were then quantiﬁed by RT-PCR
and the most relevant proteins identiﬁed using western-blotting and
immunoassays.
Results: 175 proteins were identiﬁed in NSC osteoblast secretome. Com-
pared to NSC osteoblast secretome, 13 proteins were signiﬁcantly less
secreted (Osteomodulin, CSF-1, IGFBP5, VCAM-1, IGF2, 78 kDa glucose-
regulated protein, versican, calumenin, IGFBP2, thrombospondin-4, peri-
ostin, reticulocalbin 1 and osteonectin), and 12 proteinswere signiﬁcantly
more secreted by SC osteoblasts (CHI3L1, ﬁbulin-3, SERPINE2, IGFBP6,
SH3BGRL3, SERPINE1, reticulocalbin3, alpha-2-HS-glycoprotein, TIMP-2,
IGFBP3, TIMP-1, SERPINF1). Similar changes in periostin, osteomodulin,
SERPINE1, IGFBP6, ﬁbulin-3 and CHI3L1 mRNA levels were observed.
Finally, osteomodulin and ﬁbulin-3 speciﬁc sequenceswere quantiﬁed by
western blot and immunoassays in serum and culture supernatants.
Conclusions: We highlighted some proteins differentially secreted by
the osteoblasts coming from OA subchondral bone sclerosis. These
changes contribute to explain some features observed in OA sub-
chondral bone, like the increase of bone remodeling or abnormalities in
bone matrix mineralization. Among identiﬁed proteins, osteomodulin
was found decreased and and ﬁbulin-3 increased in serum of OA
patients. These ﬁndings suggest that osteomodulin and ﬁbulin-3 frag-
ments could be biomarkers to monitor early changes in subchondral
bone metabolism in OA.
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EFFECT OF DENOSUMAB ON BONE FORMATION MARKER P1NP
H. Tanigawa y,z, T. Maeda y, K. Kumagai y, S. Imai y. y Shiga Univ. of Med.
Sci., Otsu, Japan; zKusatsu Gen. Hosp., Kusatsu-city, Shiga, Japan
Purpose: Type I procollagen N-terminal propeptide (PINP) is consid-
ered the most sensitive bone formation marker and it is useful for
monitoring osteoporosis treatment such as bone formation or anti-
resorptive therapy. In our hospital, we have administered Denosumab,
an anti-RANKL antibody as a treatment for osteoporosis. In addition to
bone mineral determination (DXA method), P1NP and serum NTx are
used as osteogenic markers and bone resorption markers, respectively,
for its therapeutic effect determination. In past reports it has been
reported that there are many cases in which P1NP falls below thestandard lower limit (17.1 mg / L) in patients using bisphosphonate (BP).
The purpose of this study was to investigate the state of P1NP value in
cases treated with denosumab.
Methods: For January 2015 - December 2016, we evaluated P1NP and
NTx for 30 patients with osteoporosis who administered denosumab at
our hospital. For each marker, the percentage of cases below the
baseline lower limit was compared.
Results: Denosumab administration resulted in P1NP below the refer-
ence lower limit value in 15 cases (50%). In NTx, there were no cases
below the reference lower limit. There were no cases of apparent
atypical femoral fractures during the follow-up period. In 24 patients
who were able to measure P1NP from the ﬁrst dose of denosumab, the
transition of the P1NP value was observed. All cases were within the
reference values before the initial prescription, but 11 cases (46%) were
lower than the reference lower limit value during administration of
denosumab for an average of 6 months.
Conclusions: Denosumab strongly suppresses bone turnover and also
decreases bone metabolism markers. When both the bone formation
marker and the bone resorption marker are below the lower limit value,
it is serologically in the state of inhibition of excessive bone turnover
(SSBT) and may contribute to atypical fracture (Kitaori et al., 2004).
In this study, P1NP was lower than the lower limit in half cases in
patients treated with denosumab, but it is difﬁcult to think of all these
cases as SSBT status. There are reports that there are cases in which
P1NP is below the lower limit in certain proportions even in BP
administered patients (Eastell et al., 2011). It is difﬁcult to use P1NP as a
hazard marker of SSBT in patients receiving bone resorption inhibitors
including denosumab. It may be necessary to set new reference values
for P1NP for cases using bone resorption inhibitors. In patients using
denosumab, P1NP fell below the reference lower limit in 50%. In
patients with bone resorption inhibitors including denosumab, it may
be necessary to examine new reference values for P1NP.
156
GENERATION AND PHENOTYPING OF A TARGETED MOUSE MODEL
OF ALKAPTONURIA
J.H. Hughes y, K. Liu y, H. Sutherland y, P.J. Wilson y, A.T. Hughes y,z,
A.M. Milan y,z, L.R. Ranganath y,z, J.A. Gallagher y, G. Bou-Gharios y.
yUniv. of Liverpool, Liverpool, United Kingdom; zRoyal Liverpool and
Broadgreen Univ. Hosp. NHS Trust, Liverpool, United Kingdom
Purpose: Alkaptonuria (AKU) is a rare autosomal recessive metabolic
disease caused by mutations in the gene homogentisate 1,2-dioxyge-
nase enzyme (HGD). Deﬁciency of HGD leads to an accumulation of
homogentisic acid in the blood and tissues. Overtime, HGA is poly-
merised to form a pigment which deposits into connective tissues,
particularly in cartilage. The cartilage becomes brittle and osteo-
arthropathy manifests in early adulthood, becoming very debilitating as
it progresses. Studying rare diseases with extreme phenotypes like AKU
aid our understanding about more common disorders like osteo-
arthritis. The current mouse model for AKU was generated by chemical
mutagenesis. To overcome the uncertainty of this model harbouring
other potentially confounding uncharacterised mutations, we gen-
erated a speciﬁc HGD (Homogentisate 1,2-dioxygenase) null mouse
with the advantage of conditional deletion.
Methods: Embryonic stem cells in the C57BL6 background with dis-
rupted HGD gene function were obtained from the Knockout Mouse
Project (KOMP). This knockout ﬁrst plasmid contains the insertion of an
IRES:lacZ trapping cassette and a promoter-driven neo cassette into the
ﬁfth intron of the HGD gene with the sixth exon ﬂanked by LoxP
sequences (HGD tm1a). Flp recombinase reverts the mutation back to
wildtype with a ﬂoxed critical exon (HGD tm1c). The model then
becomes conditional though Cre recombinase which removes the
ﬂoxed exon resulting in a mutant transcript (HGD tm1d). The Hgd tm1a
knock-out ﬁrst model is characterised here.
Results: Homozygous tm1a mice show black urine stained cage bed-
ding, one of the ﬁrst AKU symptoms. Homogentisic acid is elevated in
the homozygous tm1a in both the urine (99,575 mmol/L) and plasma
(100.5 mmol/L) compared to C57BL6 wildtype mice (urine; 0.9 mmol/L,
plasma; 1.7 mmol/L). Heterozygous tm1a and tm1c mice have levels of
HGA comparable to the C57BL6 wildtype. Ochronosis, pigmentation of
chondrocytes found within calciﬁed articular cartilage, was detected at
9 weeks in the tm1a mouse as pericellular pigmentation. At 26 and 40
weeks, numerous fully pigmented chondrocytes can be seen in the
homozygous tm1a knee cartilage with no evidence of ochronosis in
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knocked in to the tm1a mouse to disrupt gene function was used to
localise HGD expression. Whole-mount staining of several adult tissues
from tm1a mice shows positive expression in the liver and kidney
cortex but no other organs in development nor in adult mice. b-gal-
actosidase staining demonstrates transgene activity throughout the
parenchymal cells and is conﬁned to the proximal convoluted tubule
cells of the kidney cortex.
Conclusions: This novel conditional HGD null mouse exhibits all the
main symptoms of AKU. There is no evidence of haploinsufﬁciency. The
knock in LacZ transgene was successfully used to localise HGD
expression.
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3D ANALYSIS OF LOCAL GREY-LEVEL VARIANCE FROM MICRO-CT
IMAGES IS ASSOCIATED WITH OSTEOCYTE CELLULARITY IN HUMAN
OSTEOARTHRITIC SUBCHONDRAL BONE
S.S. Karhula y, M.A. Finnil€a y,z, D.M. Cooper x, D. Miller k,
M. Valkealahti ¶, A. Joukainen#,z, P. Lehenkari y,¶, H. Kr€oger#,z,
R.K. Korhonen z, H.J. Nieminen yy,y, S. Saarakkala y,¶. yUniv. of Oulu, Oulu,
Finland; zUniv. of Eastern Finland, Kuopio, Finland; xUniv. of
Saskatchewan, Saskatoon, SK, Canada; kCanadian Light Source Inc.,
Saskatoon, SK, Canada; ¶Oulu Univ. Hosp., Oulu, Finland; #Kuopio Univ.
Hosp., Kuopio, Finland; yyAalto Univ., Espoo, Finland
Purpose: Subchondral bone remodeling increases in osteoarthritis (OA)
causing alterations in bone mineralization at the tissue level as well as
changes in osteocyte morphology. Quantiﬁcation of morphological
features of osteocytes in 3D usually requires synchrotron-based micro-
computed tomography (SRmCT). Quantifying these features with con-
ventional desktop mCT systems requires extremely small samples to
provide sufﬁcient resolution (>1mm) and thus cell segmentation and
analysis from representative human osteochondral cores is challenging.
On the other hand, tissue mineral density (TMD) can be readily deter-
mined using calibration phantoms with desktop mCT systems. In prin-
ciple, texture based analysis methodswith desktop mCT systems, such as
grey-level co-occurrence matrix analysis (GLCM), could provide quan-
tiﬁable features directly associated to osteocyte cellularity and/or TMD.
In this study, we tested this hypothesis by calculating the local variance
of 3D GLCM from desktop mCT data and compared the results with
reference data from SRmCT and TMD calibration.
Methods: A total of 26 cylindrical osteochondral cores (Ø¼4mm) were
drilled from the tibial plateau and femoral condyles from 7 total knee
arthroplasty patients (approval no 78/2013, Ethical Committee of the
Northern Ostrobothnia Hospital District, Finland) and from 2 cadavers
(approval no 58/2013 & 134/2015, Research Ethics Committee of the
Northern Savo Hospital District, Finland). The samples were ﬁrst imaged
with a desktop mCT system (Skyscan 1272, Bruker microCT, Kontich,
Belgium, parameters: 50kV, 200mA, 2.75mm pixel size, 1200 projections
from 360, and with 0.5mm Al ﬁlter). Subsequently, the same samples
were imaged with SRmCT at the Canadian Light Source (Saskatoon, SK,
Canada) on the BMIT-ID (05ID-2) beamline (parameters: 31keV, 0.9mm
pixel size, and 720 projections from 180) to determine the osteocyte
cellularity in subchondral bone. To evaluate OA severity, conventional
histology with safranin O staining was performed, and the histological
sections were graded with OARSI grading system. SRmCT and mCT data-
sets were co-registered and a volume-of-interest of
1980x1980x2000mm3 was selected. Prior to analysis, a bone mask
(excluding the trabecular holes and vessel cavities) was generated from
mCT data and applied to both the SRmCT and mCT datasets. From the mCT
data the tissuemineral density (TMD) and local variance in the grey-level
values were analyzed. The local variance analysis was applied in 3D by
calculating the 2D GLCM’s through the stacks in 7 different rotational
angles and summing the GLCMs. From the summed GLCM, GLCM con-
trast (describes the local variance of the neighboring grey-level values)
was calculated. From the SRmCT data, osteocyte cellularity analyses were
performed with the CTAn software (v.1.17.7.2, Bruker microCT). Corre-
lations between the calculated GLCM contrast, TMD, and osteocyte cel-
lularity were done with Pearson’s r test. Correlation between contrast
and OARSI grade were evaluated with Spearman’s rho test.
Results: GLCM contrast increased with cellularity (R¼0.518, p¼0.007)
and OARSI grade (r¼0.585, p¼0.001). No signiﬁcant association
between GLCM contrast and the TMD (see Figure 1) was found.
Conclusions: As hypothesized, local grey-level variance in 3D from the
desktop mCT was associated with the osteocyte cellularity determinedfrom SRmCT images. Even though no signiﬁcant association between the
TMD and the GLCM features was found, signiﬁcant correlation with
OARSI grade indicated that local variability in the TMDwas also present.
The method presented here could indirectly allow analysis of osteocyte
cellularity and local variability in TMD, which both are important
descriptors of subchondral bone remodeling, from the conventional
desktop mCT systems that are widely available.158
OVARIECTOMY INDUCED BONE LOSS IS ANTAGONIZED BY PULSED
ELECTROMAGNETIC FIELDS (PEMFS) AND TNF-a AND IL-6 GENE
KNOCKOUTS IN A SIMILAR MECHANISM
S. Zhu y,z, H. He z, H. Wang z, C. Gao z,x, Q. Wang z, D. Wang j, Q. Wei z,
X. Yu ¶, C. He z,x. yArthritis Res. Canada, Univ. of British Columbia,
Richmond, BC, Canada; zRehabilitation Ctr., West China Hosp., Sichuan
Univ., Chengdu, China; x Inst. for Disaster Management and
Reconstruction, Sichuan Univ.-The Hong Kong Polytechnic Univ.,
Chengdu, China; k Sch. of Aeronautics and Astronautics, Sichuan Univ.,
Chengdu, China; ¶ Lab. of Endocrinology and Metabolism, Dept. of
Endocrinology, Natl. Key Lab. of Biotherapy/Collaborative Innovation Ctr.
of Biotherapy and Cancer Ctr., West China Hosp., Sichuan Univ.,
Chengdu, China
Purpose: Pulsed electromagnetic ﬁelds (PEMFs), as a safe and non-
invasive method, could promote in vivo and vitro osteogenesis. How-
ever, the effect and underlying mechanisms of PEMFs on post-
menopausal osteoporosis remain poorly understood. The present study
is designed to investigate the effect of PEMFs on osteoporotic bone
microarchitecture and abnormal bone metabolism together with its
potential molecular mechanisms in ovariectomized (OVX) mice with
different gene background.
Methods: Twenty 12-week Female wild-type (WT), TNFa knockout
(TNFa-/-) or IL6 knockout (IL6-/-) mice, respectively, were sham-operated
(SHAM) or subjected to OVX. After OVX,WTmice were equally assigned
to the non-treatment and PEMFs groups. Mice in PEMFs group were
subjected todaily 1-hour PEMFs exposurewith 8Hz, 3.8mT (peak value).
Then all mice were euthanized after 4 weeks. Bone mass and skeletal
microarchitecture were determined using micro-CT. Bone metabolism
was assessed by histological analysis, serum analyses and qRT-PCR.
Results: OVX signiﬁcantly increased the body weight only in WT mice
without PEMFs treatment and decreased the uterine weight in all
groups. The high bone turnover induced by OVXwas largely repaired by
TNFa and IL6 gene knockout and partially inhibited by PEMFs exposure.
The ratio of femoral trabecular bone volume to tissue volume (BV/TV),
trabecular number (Tb. N) and trabecular thickness (Tb. Th) were sig-
niﬁcantly decreased in WT mice subjected to OVX, but increased in
PEMFs group (0.89, 0.61, 0.27-fold respectively), TNFa-/- mice (1.54, 1.29,
0.30-fold respectively) and IL6-/- mice (1.18, 0.75, 0.24-fold respectively).
Furthermore, no difference in Micro-CT data analysis was found
between PEMFs group and gene knockouts mice after OVX, although
38.5% and 45.1%, respectively, increase in BV/TV and Tb. Nwere observed
in TNFa-/- mice when compared to the PEMFs group. The trends was
further conﬁrmed by bone histological analysis (H&E staining). OVX
failed to increase the number and size of TRAP-positive cells in PEMFs
group and gene knockouts mice, although the phenomenon was more
